MX367335B - Metodos y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias. - Google Patents

Metodos y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias.

Info

Publication number
MX367335B
MX367335B MX2013012472A MX2013012472A MX367335B MX 367335 B MX367335 B MX 367335B MX 2013012472 A MX2013012472 A MX 2013012472A MX 2013012472 A MX2013012472 A MX 2013012472A MX 367335 B MX367335 B MX 367335B
Authority
MX
Mexico
Prior art keywords
methods
inflammatory diseases
compositions
autoimmune
management
Prior art date
Application number
MX2013012472A
Other languages
English (en)
Other versions
MX2013012472A (es
Inventor
Gandhi Anita
Schafer Peter
Capone Lori
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2013012472A publication Critical patent/MX2013012472A/es
Publication of MX367335B publication Critical patent/MX367335B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen métodos para tratar, prevenir, o manejar enfermedades autoinmunes e inflamatorias y trastornos que incluyen pero no se limitan a espondilitis, artritis reumatoide juvenil, psoriasis, artritis psoriática, osteoartritis, espondilitis anquilosante, y artritis reumatoide por la administración de inhibidores de fosfodiesterasa 4 (PDE4) en combinación con otros terapéuticos. También se describen composiciones farmacéuticas, formas de dosificación, y kits adecuados para su uso en métodos de la invención.
MX2013012472A 2011-04-28 2012-04-27 Metodos y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias. MX367335B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480263P 2011-04-28 2011-04-28
PCT/US2012/035359 WO2012149251A1 (en) 2011-04-28 2012-04-27 Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
MX2013012472A MX2013012472A (es) 2014-05-12
MX367335B true MX367335B (es) 2019-08-15

Family

ID=46028240

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013012472A MX367335B (es) 2011-04-28 2012-04-27 Metodos y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias.

Country Status (12)

Country Link
US (1) US9272035B2 (es)
EP (1) EP2701701B1 (es)
JP (1) JP6022548B2 (es)
KR (1) KR101889757B1 (es)
CN (1) CN103635188B (es)
AU (1) AU2012249536B2 (es)
CA (1) CA2834355A1 (es)
ES (1) ES2661583T3 (es)
IL (1) IL229079A (es)
MX (1) MX367335B (es)
WO (1) WO2012149251A1 (es)
ZA (1) ZA201307918B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20150290171A1 (en) * 2012-11-09 2015-10-15 Celgene Corporation Methods for the treatment of bone loss
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
EP3096749B1 (en) * 2014-01-24 2019-05-15 Celgene Corporation Methods for the treatment of obesity using apremilast
US9994522B2 (en) 2014-05-11 2018-06-12 Mapi Pharma Ltd. Amorphous form of apremilast
CN105294534B (zh) * 2014-07-15 2020-04-10 上海优拓医药科技有限公司 制备阿普司特及其中间体的产业化方法
EP3174999A1 (en) * 2014-07-29 2017-06-07 Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
EP3188745A1 (en) * 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CN105085373B (zh) * 2015-09-01 2018-02-09 苏州大学 一种对阿普斯特产品的纯化方法
CN105388237B (zh) * 2015-12-28 2017-02-01 成都百裕金阁莱药业有限公司 阿普斯特中3‑乙酰氨基邻苯二甲酸的检测方法
BR112019015596A2 (pt) * 2017-01-27 2020-03-17 Sarudbhava Formulations Private Limited Composição farmacêutica adequada para administração tópica e método para tratar ou prevenir doenças ou distúrbios dermatológicos
CN108283620A (zh) * 2018-03-13 2018-07-17 兆科药业（广州）有限公司 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法
KR20220002488A (ko) * 2019-04-30 2022-01-06 셀진 코포레이션 아프레밀라스트 및 tyk2 억제제를 포함하는 조합 요법
DE102020129648A1 (de) * 2020-11-10 2022-05-12 Leopold MTX GmbH Pharmazeutische zusammensetzung

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
HU201577B (en) * 1988-12-20 1990-11-28 Gyogyszerkutato Intezet Process for producing cyclosporin antibiotics
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
JP2004510694A (ja) * 2000-05-08 2004-04-08 ヘインズ　デイビッド 免疫抑制性組成物
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
BRPI0519030A2 (pt) 2004-12-13 2008-12-23 Celgene Corp mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
MX2010010334A (es) * 2008-03-24 2010-10-08 Celgene Corp Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
WO2010030345A2 (en) 2008-09-10 2010-03-18 Celgene Corporation Processes for the preparation of aminosulfone compounds

Also Published As

Publication number Publication date
CN103635188B (zh) 2017-03-22
CN103635188A (zh) 2014-03-12
JP6022548B2 (ja) 2016-11-09
IL229079A (en) 2017-12-31
KR101889757B1 (ko) 2018-08-20
EP2701701B1 (en) 2018-01-24
ZA201307918B (en) 2016-01-27
KR20140038434A (ko) 2014-03-28
WO2012149251A1 (en) 2012-11-01
NZ616875A (en) 2016-01-29
CA2834355A1 (en) 2012-11-01
EP2701701A1 (en) 2014-03-05
IL229079A0 (en) 2013-12-31
MX2013012472A (es) 2014-05-12
AU2012249536A1 (en) 2013-11-07
US20120276087A1 (en) 2012-11-01
ES2661583T3 (es) 2018-04-02
JP2014516942A (ja) 2014-07-17
US9272035B2 (en) 2016-03-01
AU2012249536B2 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
MX367335B (es) Metodos y composiciones que utilizan inhibidores de pde4 para el tratamiento y manejo de enfermedades autoinmunes e inflamatorias.
PH12015500963A1 (en) Tricyclic fused thiophene derivatives as jak inhibitors
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12015502563A1 (en) Bipyrazole derivatives as jak inhibitors
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX381180B (es) Compuestos aminopirazina con propiedades antagonistas a2a.
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
MX380755B (es) Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
MX387669B (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
EP2576549A4 (en) BICYCLIC HETEROARYLATES FORMING KINASE INHIBITORS AND METHODS OF USE
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
MX2017012411A (es) Co-cristales de un inhibidor de tirosina cinasa de bruton.
MY158927A (en) Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine h4 receptor
EA201690657A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 3-(1H-ПИРАЗОЛ-4-ИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ NIK
NZ766530A (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MX373186B (es) Nuevos derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inhibidores de la cinasa inductora de nf-kappab.
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
HK1192728A (en) Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
UA106046C2 (uk) Діамінопіридинові, піримідинові і піридазинові модулятори гістамінового рецептора h4
MY198316A (en) Piperidin-4-YL Azetidine Derivatives as JAK1 Inhibitors

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration